Clotinab (abciximab) / ISU Abxis - LARVOL DELTA

Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. (PubMed, Pharmacoepidemiol Drug Saf) - "IPSIs provide a robust and practical alternative to conventional causal inference methods in pharmacoepidemiology settings where treatment assignment is highly selective and the strict positivity is violated."

Journal

Pharmacovigilance analysis of glycoprotein IIb/IIIa inhibitors: A FAERS-based signal detection study. (PubMed, Medicine (Baltimore)) - "This study compares the safety signals of 3 glycoprotein IIb/IIIa inhibitors (GPIs) - tirofiban, abciximab, and eptifibatide - using the US Food and Drug Administration Adverse Event Reporting System, aiming to guide clinical application. Abciximab signals highlight oropharyngeal, otorhinolaryngologic, and urinary tract mucosal surfaces. These findings support pharmacovigilance and warrant validation through prospective studies, with the understanding that all reported associations are based on statistical signals from a spontaneous reporting system and do not establish causality."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pancreatitis • Thrombocytopenia

High-Shear Environment Promotes Acute Carotid Stent Thrombosis in Patients With Tandem Lesions. (PubMed, J Am Heart Assoc) - "Stents placed inside the carotid bifurcation are responsible for a massive thrombus formation that could lead to stent thrombosis. The absence of mesh prevents its formation."

Journal • Atherosclerosis • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis

External quality control for light-transmission aggregometry using disease mimicking single domain antibodies or monoclonal antibodies. (ISTH 2026) - "Methods Test tubes without (normal control) and with 200 nM sdAb GPIb clone 17, which blocks VWF binding to GPIba and functionally mimics Bernard Soulier Syndrome (BSS), or 15 μg/mL abciximab, which blocks fibrinogen binding to glycoprotein IIb/IIIa and functionally mimics Glanzmann Thrombasthenia (GT), were distributed to up to 113 medical laboratories...The observed between-laboratory variation is relatively low for complex testing like LTA, especially considering that PRP was prepared independently by each laboratory. DOI*10.1016/j.rpth.2026.104076"

Hematological Disorders

Revisiting Antiplatelet Therapy in Acute Carotid Tandem Lesions. (PubMed, J Clin Med) - "Across these cohorts, glycoprotein IIb/IIIa inhibitors (GPIs), particularly tirofiban, were generally associated with lower rates of in-stent thrombosis and higher reperfusion success, with symptomatic intracranial hemorrhage (sICH) rates that appeared comparable to or lower than those reported with acetylsalicylic acid (ASA). Cangrelor, an intravenous (IV) P2Y12 inhibitor, was associated with improved stent patency and increased likelihood of complete reperfusion, although reported effects on clinical outcomes were inconsistent when compared with GPIs or ASA. Aside from abciximab, potent IV antiplatelet agents did not consistently show an increased sICH signal...However, interpretation is limited by study heterogeneity and non-randomized designs. The absence of RCTs highlights the need for prospective comparative studies and standardized periprocedural antiplatelet protocols."

Journal • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. (clinicaltrials.gov) - P4 | N=150 | Terminated | Sponsor: Seoul National University Hospital | Unknown status ➔ Terminated; The study was terminated early due to a shortage of research and analytical personnel, which prevented the completion of the study as planned

Trial termination • Cardiovascular • Myocardial Infarction

Response to the response to the letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". (PubMed, Cardiol J) - No abstract available

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

Response to letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". (PubMed, Cardiol J) - No abstract available

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

Intracoronary versus intravenous Abciximab in patients with STEMI undergoing percutaneous coronary intervention: a systematic review and meta-analysis (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Stent Thrombogenicity is Modulated by Design: Wire Crossings in Braided Stents are Focal Thrombogenic Niches. (PubMed, Thromb Haemost) - "Thrombus formation was effectively prevented in the presence of aspirin or the αIIbβ3 blocker abciximab. Computational fluid dynamics indicated that the wire crossings of braided stents generate a prothrombotic shear environment, with flow recirculation and stagnation regions leading to thrombus formation, as demonstrated by a macroscale in silico simulation.Design plays a major role in thrombus formation on stent wires, with braided stents being more thrombogenic than laser-cut stents."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

ACUTE THROMBOTIC LEFT MAIN CORONARY OSTIAL OCCLUSION- SAILING THROUGH THE STORM (ACC 2026) - "After serial balloon dilatations, TIMI-1 flow was achieved which subsequently improved to TIMI-2 flow following administration of intracoronary abciximab, adenosine and adrenaline... In patients with ST elevation myocardial infarction with cardiogenic shock, circulatory support with Impella is crucial in improving outcomes before urgent revascularization. Nevertheless, the absence of these (in resource constrained settings) should not deter us from urgent coronary revascularization."

Cardiovascular • Myocardial Infarction • Renal Disease • Respiratory Diseases • Thrombosis

COMPARISION OF ROUTINE VASCULAR BED PREPARATION VERSUS NEED BASED VASCULAR BED PREPARATION IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (ACC 2026) - "Vasodilators included abciximab, adenosine, diltiazem, adrenaline, and nitrate. Despite advances in primary PCI, no-reflow continues to pose a major limitation. Targeted distal pharmacotherapy using the perforated balloon approach provides a practical, efficient, and economical solution to mitigate this complication."

Clinical

Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making? (PubMed, Stroke) - "Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial."

Journal • Review • Cardiovascular • Ischemic stroke • Thrombosis

Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. (PubMed, Transfusion) - "PRCFC and LIFC retained critical hemostatic functions of VWF and fibrinogen to support platelet adhesion and aggregation during physiologic shear. PRCFC and LIFC represent a therapeutic option for early treatment of massive hemorrhage."

Journal • Hematological Disorders • Infectious Disease • Thrombosis

Enhancing hemostasis in glanzmann thrombasthenia via protein S inhibition (ASH 2025) - "Acute bleeds are primarily managed withplatelet transfusions, and recombinant factor VIIa is used for refractory cases or perioperative support.HMB-001, a novel bispecific antibody, is under investigation as the first prophylactic therapy for GT.Protein S (PS) is a natural anticoagulant that functions as a cofactor for activated protein C, and tissuefactor pathway inhibitor, and independently regulates the prothrombinase and tenase complexes,thereby reducing thrombin generation...Clot retraction was assessed in healthy donor PRP treated with anti-PS antibody, anti-αIIbβ3 antibody (abciximab), both antibodies, or vehicle... A single PS-siRNA injection in αIIbβ3⁻/⁻ mice prevented overt bleeding at necropsy, unlike PBS-treated controls, which showed visible mucocutaneous and GI bleeding. This correlated with a significantincrease in endogenous thrombin potential (ETP): 774 ± 125 nM in PS-siRNA–treated mice vs. 438 ± 81 nMin PBS controls (n = 2–3), indicating that..."

Gastrointestinal Disorder • Hematological Disorders • Hemophilia • Rare Diseases • PROS1 • TINCR

Mechanobiology of Megakaryocyte-Driven Contraction of Plasma Clots (ASH 2023) - "In addition, contraction of plasma clots by activated iMKs was abrogated by 10μg/ml abciximab, that prevented binding of fibrin(ogen) to integrin a IIbb 3 receptors... We have demonstrated a hitherto unknown ability of individual MKs to shrink fibrin clots and deciphered the cellular mechanisms of contractility of iPSC-derived MKs. The molecular mechanisms of MK-driven fibrin clot shrinkage were shown to be similar or identical to those of activated platelets, involving non-muscle myosin II activity, actin polymerization, and integrin αIIbβ3-fibrin interactions. Our findings provide a novel mechanistic insight into mechanobiology of MKs that may play a role in modulating the properties of hemostatic blood clots and thrombi."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis

Red Blood Cell Aggregation within a Blood Clot Causes Clot Shrinkage (ASH 2024) - "This process was insensitive to the inhibitors of platelet contractility, such as blebbistatin, latrunculin A, and abciximab...This study provides compelling evidence that RBCs play a role in blood clot shrinkage unrelated to platelets, suggesting that aggregating RBCs contribute actively to the blood clot contraction. Physiologically, the RBC-induced clot shrinkage may reinforce the platelet-driven blood clot contraction and/or promote clot compaction when there are few or dysfunctional platelets."

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

OPTIMAL INTRAPROCEDURAL ANTIPLATELET STRATEGY DURING RESCUE STENTING FOR REFRACTORY LARGE VESSEL OCCLUSION: A SUB-STUDY OF THE RESISTANT REGISTRY (WSC 2025) - "Antiplatelet regimens were classified as intravenous (IV-APT) (cangrelor, tirofiban, eptifibatide, abciximab), single oral (aspirin, clopidogrel, ticagrelor), or dual oral therapy. ConclusionsIntraprocedural intravenous antiplatelet therapy was associated with improved procedural success and reduced re-occlusion without a significant impact on hemorrhagic or functional outcomes. These findings support the procedural safety of IV antiplatelets and highlight their potential benefit in optimizing reperfusion outcomes during rescue stenting."

Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents. (PubMed, Blood Vessel Thromb Hemost) - "Platelet accumulation was inhibited by abciximab but not aspirin, whereas coagulation inhibitors (5G9, argatroban, heparin) markedly reduced thrombus formation. These findings support that the Endo-chip laser-injury model incorporates key features of thrombus formation after endothelial injury, and provides a humanized, in vitro, alternative or auxiliary to mouse models for preclinical studies and antithrombotic drug development."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Thrombosis • ANXA5

Role of routine vascular bed preparation in patients undergoing primary percutaneous coronary intervention (ESC-WCC 2025) - "Group A: -Intracoronary vasodilator (abciximab, adenosine, diltiazem, adrenaline, nitrate) via guiding catheter followed by primary PCI. Conclusion- No-reflow is not infrequent following PCI especially in setting of primary PCI. Distal drug delivery through perforated balloon technique is easy, reproducible, less time consuming and cost-effective technique to prevent no reflow."

Clinical • Cardiovascular • Myocardial Infarction • Reperfusion Injury • Thrombosis

Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases. (PubMed, Front Neurol) - "No fatal hemorrhages occurred following abciximab administration. Abciximab was safe and seemed effective for the management of thromboembolic complications during endovascular treatment of intracranial aneurysms, without increasing infarct burden or compromising functional outcomes in affected patients."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling. (PubMed, Sci Rep) - "Drug repurposing and molecular docking suggested abciximab and paclitaxel as potential therapeutic agents targeting CD40, while ivermectin emerged as a strong candidate for LRP1 binding. In conclusion, our integrative bioinformatics frameworks links genomics and transcriptomics with network biology and structural modeling, providing valuable insights into the molecular mechanisms of AAA and potential therapeutic strategies."

Clinical • IO biomarker • Journal • Retrospective data • Cardiovascular • Infectious Disease • CD40 • LRP1

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. (PubMed, Pharmacoepidemiol Drug Saf) - "Our numerical results support the use of SBW in situations where IVs or near-IVs may lead to practical violations of positivity assumptions."

Clinical • Journal

The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab. (PubMed, Cardiol J) - "In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The internal standard, abciximab, used the peptide VQWLQAGK with parent and daughter ions at m/z 471.26 and 590.32, respectively. Matrix effects at low and high QC levels confirmed consistency, with accuracy and precision for atezolizumab and bevacizumab exceeding ICH guidelines. This optimized method offers a valuable tool for pharmacokinetic profiling of atezolizumab and bevacizumab in rat plasma, providing insights for therapeutic monitoring and drug development."

Journal • PK/PD data • Preclinical